Binghui Hou

Dr. Binghui Hou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2023 in Neuroscience Letters
Verified
Journal Article
Closed access
Xiaohui SunXiaohui Sun
Xiaohui Sun
QTQing Tian
Qing Tian
ZYZhengjie Yang
Zhengjie Yang
YLYumei Liu
Yumei Liu
CLChengqian Li
Chengqian Li
XAXie Anmu
Xie Anmu

23 July 2024 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
YLYumei Liu
Yumei Liu
KQKunpeng Qin
Kunpeng Qin
CJChunyan Jiang
Chunyan Jiang
JGJinzhao Gao
Jinzhao Gao
BHBinghui Hou
Binghui Hou
XAXie Anmu
Xie Anmu
Parkinson’s disease (PD) is closely related to iron accumulation and inflammation. Emerging evidence indicates that TMEM106B plays an essential role in PD. But whether TMEM106B could act on neuroinflammation and iron metabolism in PD has not yet been investigated. The aim of this study was to investigate the pathological mechanisms of inflammation and iron metabolism of TMEM106B in PD. 1-methyl-4-phenylpyridinium (MPP+)- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced SH-SY5Y cells and mice were treated with LV-shTMEM106B and AAV-shTMEM106B to construct PD cellular and mouse models. Pole tests and open-field test (OFT) were performed to evaluate the locomotion of the mice. Immunohistochemistry and iron staining were used to detect TH expression and iron deposition in the SN. Iron staining was used to measure the levels of iron. Western blotting was used to detect the expression of inflammatory factors (tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)), NOD-like receptor protein 3 (NLRP3) inflammasome, divalent metal transporter 1 (DMT1), and Ferroportin1 (FPN1)). Knockdown of TMEM106B improved motor ability and rescued dopaminergic (DA) neuron loss. TMEM106B knockdown attenuated the increases of TNF-α, IL-6, NLRP3 inflammasome, and DMT1 expression in the MPP+ and MPTP-induced PD models. Furthermore, TMEM106B knockdown also increases the expression of FPN1. This study provides the first evidence that knockdown of TMEM106B prevents dopaminergic neurodegeneration by modulating neuroinflammation and iron metabolism.

25 March 2021 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
XSXiaohui Sun
Xiaohui Sun
XXXiang Xu
Xiang Xu
YWYumei Wang
Yumei Wang
BHBinghui Hou
Binghui Hou
Tingting LuoTingting Luo
Tingting Luo
FNFeng Ning
Feng Ning

23 November 2022 in Frontiers in Neuroscience
Verified
Journal Article
Open access
MTMingzhu Tao
Mingzhu Tao
KDKaixin Dou
Kaixin Dou
YXYijie Xie
Yijie Xie
BHBinghui Hou
Binghui Hou
XAXie Anmu
Xie Anmu
Background: In Parkinson’s disease (PD), levels of cerebrospinal fluid (CSF) biomarkers and progression of non-motor symptoms are associated, but the specifics are not yet clear.Objective: The aim of this study was to investigate the associations of non-motor symptoms with CSF biomarkers in PD.Materials and methods: We assessed 487 individuals from the Parkinson’s Progression Markers Initiative (PPMI), consisting of 155 healthy controls (HCs) and 332 individuals with PD. Patients with PD were grouped according to non-motor symptoms and compared CSF α-synuclein (α-syn), amyloid-beta 1-42 (Aβ1–42), and total tau (t-tau) levels. Multiple linear regressions were used in baseline analysis and linear mixed-effects models in longitudinal analysis. Analyses of mediating effects between cognition and CSF biomarkers were also performed.Results: At baseline, PD patients with cognitive impairment (PDCI) exhibited significantly lower CSF α-syn (β = −0.1244; P = 0.0469), Aβ (β = −0.1302; P = 0.0447), and t-tau (β = −0.1260; P = 0.0131) levels than PD patients without cognitive impairment (PDCU). Moreover, a faster decline of α-syn (β = −0.2152; P = 0.0374) and Aβ (β = −0.3114; P = 0.0023) and a faster rise of t-tau (β = −0.1534; P = 0.0274) have been found in longitudinal analysis. The Aβ positive group showed an earlier decline in cognitive performance (β = −0.5341; P = 0.0180) compared with the negative Aβ group in both analyses. In addition, we found that PD patients with probable rapid eye movement sleep behavior disorder (pRBD) showed decreased CSF α-syn (β = −0.1343; P = 0.0033) levels. Finally, mediation analysis demonstrated that olfactory function partially mediated the relationship between cognition and CSF biomarkers levels.Conclusion: Our study shows that CSF biomarkers are associated with cognition at baseline and longitudinally. Cognitive impairment is more severe in patients with a heavier Aβ burden. CSF α-syn decreased in PD patients with pRBD. This study suggests that early recognition of the increased risk of non-motor symptoms is important for disease surveillance and may be associated with the pathological progression of CSF markers.

28 October 2024 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Open access
YLYumei Liu
Yumei Liu
KQKunpeng Qin
Kunpeng Qin
KDKaixin Dou
Kaixin Dou
JRJiwen Ren
Jiwen Ren
BHBinghui Hou
Binghui Hou
XAXie Anmu
Xie Anmu
TMEM106B, a lysosomal transmembrane protein, has been reported to be associated with Parkinson's disease (PD). However, the precise physiopathologic mechanism of TMEM106B in PD remains unclear. This study aimed to explore the influence of TMEM106B on the autophagy-lysosome pathway (ALP) in PD. 55 patients with PD and 40 healthy controls were enrolled. RT-qPCR and ELISA were employed to assess the levels of TMEM106B. In vitro and in vivo models of PD, Lentivirus-shTMEM106B and AAV-shTMEM106B were used to knockdown the expression of TMEM106B. Behavioral experiments, western blot, immunofluorescence, and immunohistochemistry were used to detect the effect of TMEM106B on the ALP process. We found that the levels of TMEM106B were increased in the PD patients and PD models. TMEM106B knockdown markedly improved the motor deficits and tyrosine hydroxylase (TH) expression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice. TMEM106B knockdown promoted α-syn clearance by regulating the ALP process in MPP+-induced SH-SY5Y cells and MPTP-treated mice. Further studies revealed that TMEM106B knockdown might activate ALP through activating AMPK-mTOR-TFEB axis. Furthermore, TMEM106B may play a vital role in the ALP by mediating the expression of TDP43. Taken together, our study suggests that TMEM106B knockdown mediates the ALP pathway, leading to a decrease in α-syn, providing a new direction and perspective for the regulation of autophagy in PD.

20 July 2023 in Neuroscience Letters
Verified
Journal Article
Closed access
QTQing Tian
Qing Tian
Xiaohui SunXiaohui Sun
Xiaohui Sun
CLChengqian Li
Chengqian Li
YYYong Yang
Yong Yang
BHBinghui Hou
Binghui Hou
XAXie Anmu
Xie Anmu